Literature DB >> 18264082

Epigenetic instability is rare in fibrolamellar carcinomas but common in viral-associated hepatocellular carcinomas.

Perumal Vivekanandan1, Michael Torbenson.   

Abstract

Fibrolamellar carcinomas have a unique predilection for younger individuals and arise in livers without recognizable liver disease. In contrast to typical hepatocellular carcinomas, fibrolamellar carcinomas show few chromosomal changes and lack mutation in key genes such as TP53 and CTNNB1. Epigenetic instability, manifesting as methylation of important tumor suppressor gene promoters, has not been investigated in fibrolamellar carcinomas. Thus, the methylation status of 11 tumor suppressor gene promoters was investigated using methylation-specific PCR: RASSF1, CDH1, CDKN2B, HPP1, CDKN2A, GSTP1, P16, RARA, FLJ13081, SOCS1, and TP53. Nine fibrolamellar carcinomas were studied including primary tumors (N=5) and metastatic deposits (N=4) along with control groups of typical hepatocellular carcinoma arising in livers with (N=21) and without cirrhosis (N=10). In fibrolamellar carcinomas, RASSF1A and CDH1 (e-cadherin) were the most commonly methylated genes with 80-100% of tumors methylated. However, overall fibrolamellar carcinomas showed low levels of methylation with no differences between fibrolamellar carcinomas and their paired normal livers. However, fibrolamellar carcinomas showed significantly less methylation than hepatocellular carcinomas that arose in the background of viral cirrhosis. Overall, methylation was most strongly linked to viral cirrhosis. In conclusion, fibrolamellar carcinoma shows low levels of methylation. In contrast, higher levels of promoter methylation are associated with hepatocellular carcinomas that arise in the setting of viral induced cirrhosis.

Entities:  

Mesh:

Year:  2008        PMID: 18264082     DOI: 10.1038/modpathol.2008.32

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  14 in total

1.  TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.

Authors:  Raissa C Andrade; Maria A F D de Lima; Paulo A S de Faria; Fernando R Vargas
Journal:  Fam Cancer       Date:  2018-01       Impact factor: 2.375

2.  A young woman with liver cancer.

Authors:  Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

3.  Role of RASSF1A promoter methylation in the pathogenesis of hepatocellular carcinoma: a meta-analysis of 21 cohort studies.

Authors:  Yong-Shuang Li; Qiang Xie; Da-Ye Yang; Yuan Zheng
Journal:  Mol Biol Rep       Date:  2014-02-25       Impact factor: 2.316

4.  Hepatitis B virus replication induces methylation of both host and viral DNA.

Authors:  Perumal Vivekanandan; Hubert Darius-J Daniel; Rajesh Kannangai; Francisco Martinez-Murillo; Michael Torbenson
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

5.  Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Authors:  Basile Njei; Venkata Rajesh Konjeti; Ivo Ditah
Journal:  Gastrointest Cancer Res       Date:  2014-03

6.  Molecular characteristics of fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Péter Törzsök; Ilona Kovalszky; Tamás Barbai; Erzsébet Rásó; Gábor Lotz; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2012-08-08       Impact factor: 3.201

7.  Cell cycle biology of fibrolamellar hepatocellular carcinoma.

Authors:  Sadhna Dhingra; Wei Li; Dongfeng Tan; Maryam Zenali; Haizeng Zhang; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-11-02

8.  Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver.

Authors:  Wolfgang Tränkenschuh; Florian Puls; Matthias Christgen; Cord Albat; Albert Heim; Jeanette Poczkaj; Peer Fleming; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

9.  Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features.

Authors:  Gabriel G Malouf; Tomomitsu Tahara; Valérie Paradis; Monique Fabre; Catherine Guettier; Jumpei Yamazaki; Hi Long; Yue Lu; Noël J-M Raynal; Jaroslav Jelinek; Roger Mouawad; David Khayat; Laurence Brugières; Eric Raymond; Jean-Pierre J Issa
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 10.  Fibrolamellar Carcinoma: Recent Advances and Unresolved Questions on the Molecular Mechanisms.

Authors:  Gadi Lalazar; Sanford M Simon
Journal:  Semin Liver Dis       Date:  2018-02-22       Impact factor: 6.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.